论文部分内容阅读
目的 观察含紫杉类药物的联合化疗对晚期恶性肿瘤的临床疗效及安全性。方法 用含紫杉类药物 (紫杉醇Paclitaxel,泰索帝Taxotere)的联合化疗方案治疗 3 7例中晚期恶性肿瘤患者 ,可评价疗效者 3 6例 ,其中非小细胞肺癌 (NSCLC) 11例 ,小细胞肺癌 (SCLC) 3例 ,乳腺癌 15例 ,胃癌 2例 ,大肠癌 5例。结果 CR 3例 ,PR 14例 ,SD 13例 ,PD 6例 ,总有效率 47.2 % ,WBC下降占 91.7% ,脱发占 88.9% ,肌肉关节痛占 69.4% ,指趾麻木占 5 8.3 %。结论 紫杉类药物对NSCLC ,乳腺癌 ,大肠癌及伴有肝转移的恶性肿瘤有较高的疗效 ,且毒性可耐受
Objective To observe the clinical efficacy and safety of combination chemotherapy with taxanes for advanced malignant tumors. Methods Thirty-seven patients with metaphase and advanced malignant tumors were treated with a combination chemotherapy with paclitaxel (Paclitaxel, taxotere). 36 patients could be evaluated for efficacy, including 11 cases of non-small cell lung cancer (NSCLC). There were 3 cases of cell lung cancer (SCLC), 15 cases of breast cancer, 2 cases of gastric cancer, and 5 cases of colorectal cancer. Results There were 3 cases of CR, 14 cases of PR, 6 cases of SD, and 4 cases of PD. The total effective rate was 47.2%, WBC decreased 91.7%, hair loss accounted for 88.9%, muscle and joint pain accounted for 69.4%, and finger and toe numbness accounted for 58.3%. Conclusion Taxane drugs have high curative effect on NSCLC, breast cancer, colorectal cancer and malignant tumors with hepatic metastases, and the toxicity can be tolerated.